Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.

Article Details

Citation

Copy to clipboard

Miceli MH, Kauffman CA

Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.

Clin Infect Dis. 2015 Nov 15;61(10):1558-65. doi: 10.1093/cid/civ571. Epub 2015 Jul 15.

PubMed ID

26179012 [ View in PubMed

]

Abstract

Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double-blind comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole. An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole. In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole. As clinical experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.

DrugBank Data that Cites this Article

Drugs

Isavuconazonium

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Isavuconazole	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details

Drug Transporters

Drug	Transporter	Kind	Organism	Pharmacological Action	Actions
Isavuconazonium	P-glycoprotein 1	Protein	Humans	No	Inhibitor	Details